Transcatheter Aortic Valve Replacement Outcomes in End-Stage Renal Disease Patients on Hemodialysis Requiring Midodrine.

Publication Title

Struct Heart

Authors

Ethan C Korngold, Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, Oregon, USAFollow
Ruyun Jin, Center for Cardiovascular Analytics, Research, and Data Science; Providence St Joseph Heart Institute, Portland, ORFollow
Kateri Spinelli, Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, Oregon, USAFollow
V Kumar, Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, Oregon, USAFollow
Brydan Curtis, Providence Spokane Heart Institute, Spokane, Washington, USAFollow
Sameer Gafoor, Swedish Heart and Vascular, Seattle, WA, USA.Follow
Derek Phan, Swedish Heart & Vascular Institute, Cherry Hill Campus, Seattle, Washington, USA
Daniel Spoon, Providence International Heart Institute of Montana, Missoula, Montana, USAFollow
Aidan Raney, Providence St. Joseph Hospital-Orange, Orange, California, USAFollow
Lisa McCabe, Providence Regional Medical Center Everett, Everett, Washington, USAFollow
Brandon Jones, Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, Oregon, USAFollow

Document Type

Article

Publication Date

5-1-2023

Keywords

washington; oregon; montana; california; swedish; pshmc; cards; cards publication; missoula; orange; everett; prmc; End stage renal disease; Midodrine; Survival; Transcatheter aortic valve replacement

Abstract

BACKGROUND: Patients with dialysis-dependent end-stage renal disease (ESRD) taking midodrine may be at high risk for poor outcomes following transcatheter aortic valve replacement (TAVR). We evaluated dialysis-dependent ESRD patients taking midodrine.

METHODS: We conducted a retrospective analysis of non-clinical trial TAVR patients from February 2012 to December 2020 from 11 facilities in a Western US health system. Patient groups included ESRD patients on midodrine before TAVR (ESRD [+M]), ESRD patients without midodrine (ESRD [-M]), and non-ESRD patients. The endpoints of 30-day and 1-year mortality were represented by Kaplan-Meier survival estimator and compared by log-rank test.

RESULTS: Forty-five ESRD (+M), 216 ESRD (-M), and 6898 non-ESRD patients were included. ESRD patients had more comorbid conditions, despite no significant difference in predicted Society of Thoracic Surgeons mortality risk between ESRD (+M) and ESRD (-M) (8.7% vs. 9.2%,

CONCLUSIONS: Our experience suggests ESRD patients on midodrine are a higher acuity population with worse survival after TAVR, compared to ESRD patients not on midodrine. These findings may help with risk stratification for ESRD patients undergoing TAVR.

Clinical Institute

Cardiovascular (Heart)

Clinical Institute

Kidney & Diabetes

Specialty/Research Institute

Center for Cardiovascular Analytics, Research + Data Science (CARDS)

Specialty/Research Institute

Nephrology

Specialty/Research Institute

Cardiology

DOI

10.1016/j.shj.2023.100163